Clinical trial
7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic…
NCT00115089 · Rigel Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00115089 |
|---|---|
| Title | 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis |
| Official title | A Phase II Multi-Center, Randomized, Double-Blind, Active and Placebo-Controlled 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis |
| Lead sponsor | Rigel Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rhinitis, Allergic, Seasonal |
| Intervention type | Drug |
| Interventions | R926112, Beclomethasone dipropionate |
| Enrollment | 375 |
| Start date | Jul 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Jun 21, 2005 |
| Last update posted | Nov 11, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: